Acquisition leverage Following Certara's acquisition in December 2023, there is an opportunity to engage Certara’s extended biosimulation portfolio for joint go-to-market strategies, co-selling, or integration of MADI capabilities into Certara’s offerings to accelerate customer adoption.

MID3 leadership Applied BioMath positions as a leader in model-informed drug discovery and development (MID3); target biotech and pharma companies pursuing predictive dosing, optimization of therapeutic windows, and de-risked clinical programs with high potential ROI.

Strategic collaborations Existing and past collaborations with Celsius Therapeutics, Monte Rosa Therapeutics, and other biotech players indicate openness to partner on pharmacokinetic/pharmacodynamic modeling, systems pharmacology, and monoclonal antibody programs—prospects for new collaboration deals or expanded scopes.

Pursue funding-backed projects Recent grants and ongoing platform development for dosing optimization and Immunocytokines present a pathway to frame proposals around funded programs, which can be used to secure longer-term contracts or multi-project engagements with risk-sharing components.

SMB to mid-market focus With 11-50 employees and revenue in the low millions, target small to mid-market biotech firms that need specialized modeling and simulation to accelerate R&D timelines, offering scalable MID3 services, pilot programs, and modular packages as entry points.